# Evaluating the Efficacy of Artificial Intelligence-based Computer Aided Diagnosis Software That Assists in Determining Whether or Not to Conduct Amyloid PET for the Diagnosis of Alzheimer's Disease by Predicting Amyloid PET Positivity in Mild Cognitive Impairment Patients

> **NCT05383053** · — · COMPLETED · sponsor: **Neurozen Inc.** · enrollment: 227 (actual)

## Conditions studied

- Alzheimer Disease
- Mild Cognitive Impairment

## Interventions

- **DEVICE:** NeuroAI

## Key facts

- **NCT ID:** NCT05383053
- **Lead sponsor:** Neurozen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-22
- **Primary completion:** 2022-08-10
- **Final completion:** 2022-09-08
- **Target enrollment:** 227 (ACTUAL)
- **Last updated:** 2022-09-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05383053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05383053, "Evaluating the Efficacy of Artificial Intelligence-based Computer Aided Diagnosis Software That Assists in Determining Whether or Not to Conduct Amyloid PET for the Diagnosis of Alzheimer's Disease by Predicting Amyloid PET Positivity in Mild Cognitive Impairment Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05383053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*